SEC Form 4 · accession 0001209191-15-013084
ANTARES PHARMA, INC. · ATRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert F Apple
Officer — Executive Vice President & COO
Period of report
Feb 10, 2015
Accepted (ET)
Feb 12, 2015 · 7:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001016169
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 10, 2015 | A | 12,519 | $0.00 | A | 331,398 | D | |
| Common Stock | Feb 10, 2015 | F | 4,779 | $2.36 | D | 326,619 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On July 6, 2012, Mr. Apple received a performance stock unit award under the 2008 Equity Compensation Plan. The target number of shares under the award is 25,039 shares, and the award is contingent upon the Company's achieving certain performance goals over the three-year period beginning January 1, 2012 and ending December 31, 2014. The 12,519 shares reported here represent the number of shares vested on February 10, 2015 upon the Company's achievement of a performance goal. 12,520 shares of the award remain subject to performance goals and may be earned by Mr. Apple pursuant to the terms of the award. Until earned, they have been removed from the amount of securities beneficially owned.